Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study

We aimed to evaluate the feasibility of concurrent chemoradiotherapy (CRT) with capecitabine and cisplatin in patients with squamous cell carcinoma of the esophagus. Eighteen patients with esophageal cancer were enrolled on the study. The chemotherapy during CRT consisted of two cycles of intravenou...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Korean medical science 2009, 24(1), 127, pp.120-125
Main Authors: Lee, Soo Jung, Ahn, Byung Min, Kim, Jong Gwang, Sohn, Sang Kyun, Chae, Yee Soo, Moon, Joon Ho, Lee, Eung Bae, Kim, Jae Chul, Park, In Kyu, Jeon, Seong Woo
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Capecitabine
Cisplatin - administration & dosage
Combined Modality Therapy
Deoxycytidine - administration & dosage
Deoxycytidine - analogs & derivatives
Esophageal Neoplasms - drug therapy
Esophageal Neoplasms - radiotherapy
Esophageal Neoplasms - therapy
Female
Fluorouracil - administration & dosage
Fluorouracil - analogs & derivatives
Humans
Male
Middle Aged
Neoplasm Staging
Original
Severity of Illness Index
Survival Rate
Treatment Outcome
의학일반
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We aimed to evaluate the feasibility of concurrent chemoradiotherapy (CRT) with capecitabine and cisplatin in patients with squamous cell carcinoma of the esophagus. Eighteen patients with esophageal cancer were enrolled on the study. The chemotherapy during CRT consisted of two cycles of intravenous cisplatin of 60 mg/m(2) on day 1 and oral capecitabine 825 mg/m(2) twice daily from day 1 to 14 at 3-week intervals. The radiotherapy (2.0 Gy fraction/day to a total dose of 60 Gy) was delivered to the primary tumor site and regional lymph node. After concurrent CRT, 2 cycles of capecitabine (1,000 mg/m(2) b.i.d from days 1 to 14) plus cisplatin (60 mg/m(2) on day 1) were added every 3 weeks. All patients completed the planned treatment. After the chemoradiotherapy, 12 complete responses (CR, 66.7%) and 6 partial responses (PR, 33.3%) were confirmed. Grade 3 or 4 neutropenia only occurred in 2 patients, plus no treatment-related death was observed. At a median follow-up duration of 14.9 months, the estimated overall survival and progression-free survival rate at 2-yr was 70.7% and 54.4%, respectively. Concurrent CRT with capecitabine and cisplatin was found to be well-tolerated and effective in patients with esophageal cancer.
ISSN:1011-8934
1598-6357
DOI:10.3346/jkms.2009.24.1.120